Reversible sequestration of nitric oxide by hemoglobin during hemodialysis in end-stage renal disease.
BACKGROUND
During hemodialysis, patients whose plasma concentrations of nitric oxide (NO) products increase reportedly experience hypotension. Therefore, whether NO bound to hemoglobin (Hb) could contribute to various clinical and laboratory changes during hemodialysis was explored in patients with end-stage renal disease (ESRD).


METHODS
Ten patients were studied during 3 hemodialysis treatments with samples of blood analyzed for RBC nitrosyl Hb (HbNO), L-arginine, asymmetric dimethylarginine (ADMA), plasma nitrite+nitrate (NOx), and buffy coat NO synthase (NOS) activities.


RESULTS
HbNO before and during hemodialysis varied considerably. Those with higher predialysis levels had lower HbNO values during dialysis, whereas HbNO levels in those with lower levels before dialysis increased. Plasma NOx did not correlate with HbNO, but change in HbNO in the first hour and change in NOx in the first 2 hours correlated with drop in diastolic and systolic blood pressures (BP), respectively. HbNO concentrations increased in patients with >35% drop in systolic BP, whereas in those with <35% drop, HbNO concentrations decreased. HbNO levels adjusted by the hematocrit showed a drop in HbNO for the <35% group and a >3-fold increase in the >35% group. HbNO levels were higher in men than in women, and levels and changes correlated with the hematocrit, skin temperatures, plasma ADMA, arginine, and buffy coat NOS.


CONCLUSIONS
In patients with >35% drop in systolic BP, NO was scavenged by Hb in the circulating RBCs, undoubtedly attenuating the degree of hypotension. These data indicate that the amount of NO that is scavenged or released by Hb in the circulating RBCS during dialysis is highly variable and reversible. Various predialysis factors relate to the concentration of HbNO before and during dialysis, which in turn influence clinical findings that occur during the interdialytic period.
Kang
E S
ES
Department of Pediatrics, University of Tennessee, Memphis 38163, USA. eskang@pol.net
Miles
D E
DE
Tevlin
M T
MT
Cates
T B
TB
Acchiardo
S R
SR
D000740:Anemia / Q000188:drug therapy / Q000209:etiology; D001120:Arginine / Q000031:analogs & derivatives / Q000097:blood; D004921:Erythropoietin / Q000494:pharmacology / Q000627:therapeutic use; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis*; D006801:Humans; D007022:Hypotension / Q000097:blood / Q000209:etiology*; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy; D009566:Nitrates / Q000097:blood; D009569:Nitric Oxide / Q000097:blood* / Q000737:chemistry; D019001:Nitric Oxide Synthase / Q000097:blood; D009573:Nitrites / Q000097:blood; D006435:Renal Dialysis / Q000009:adverse effects*; D012881:Skin Temperature
D006454:Hemoglobins; D009566:Nitrates; D009573:Nitrites; C008657:nitrosyl hemoglobin; D004921:Erythropoietin; D009569:Nitric Oxide; C018524:N,N-dimethylarginine; D001120:Arginine; D019001:Nitric Oxide Synthase